Evidence map›Paper›PMID 30689485›Full record

ArticleUpsala journal of medical sciences2019

A framework for monitoring of new drugs in Sweden.

Thomas Cars, Lars Lindhagen, Johan Sundström

Abstract read
In one paragraph

Article in Upsala journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thomas Carsa Department of Medical Sciences , Uppsala University , Uppsala , Sweden.
Lars Lindhagenb Uppsala Clinical Research Center Uppsala University , Uppsala , Sweden.
Johan Sundströma Department of Medical Sciences , Uppsala University , Uppsala , Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to monitor the net public health benefit of new drugs, especially in the light of recent stepwise approval approaches, there is a need to optimize real-time post-marketing evaluation of new drugs using data collected in routine care. Sweden, with its unique possibilities for observational research, can provide these data. We herein propose a framework for continuous monitoring of the effectiveness, safety, and cost-effectiveness of new drugs, using prospectively determined protocols designed in collaboration between all relevant stakeholders. We believe that this framework can be a useful tool for healthcare authorities and reimbursement agencies in the introduction of new drugs.

Indexed as

Drug and Narcotic ControlResearch DesignClinical Trials as TopicComparative Effectiveness ResearchCost-Benefit AnalysisData CollectionDrug ApprovalDrug IndustryHumansObservational Studies as TopicPharmacoepidemiologyPropensity ScoreProspective StudiesPublic HealthSwedenComparative effectiveness researchpharmacoepidemiologypropensity scorereal-world evidencesequential monitoring

Identifiers

PMID30689485
PMCPMC6450577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.